Author

M. C. Dallos

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:flow cytometry· 1 Organism:human· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1

Frequent Co-Authors

C. G. Drake· 2 shared C. R. Ager· 2 shared A. Califano· 1 shared A. Obradovic· 1 shared A. Z. Obradovic· 1 shared B. Izar· 1 shared C. B. Anderson· 1 shared C. Spina· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

C. G. Drake

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response

C. R. Ager, M. Zhang, M. Chaimowitz, S. Bansal, A. Obradovic, M. Rogava, J. C. Melms, P. McCann, C. Spina, C. G. Drake, M. C. Dallos, B. Izar

The paper identifies KLRG1-expressing CD4 T cell subsets linked to tumor progression and immunotherapy response using longitudinal flow cytometry and machine learning.

bioRxiv · Jan 1, 2023Immunology

Single-Cell RNAseq Analysis Reveals Robust Anti-PD-1-Mediated Increase of Immune Infiltrate in Metastatic Castration-Sensitive Prostate Cancer

J. E. Hawley, A. Z. Obradovic, M. C. Dallos, E. A. Lim, K. Runcie, C. R. Ager, J. M. McKiernan, C. B. Anderson, G. J. Decastro, J. L. Weintraub, R. K. Virk, I. Lowy, J. Hu, M. G. Chaimowitz, X. V. Guo, , C. G. Drake

The paper analyzes single-cell RNAseq data from metastatic castration-sensitive prostate cancer patients treated with anti-PD-1 immunotherapy, showing increased immune infiltrate and identifying therapy-resistant tumor subpopulations and druggable targets.

bioRxiv · May 6, 2022 · PreprintCancer Biology